RG 7652

Drug Profile

RG 7652

Alternative Names: MPSK-3169A; RG-7652

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genentech; Roche
  • Class Antihyperlipidaemics; Monoclonal antibodies
  • Mechanism of Action PCSK9 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Coronary disorders; Hyperlipidaemia; Metabolic disorders

Most Recent Events

  • 16 Dec 2016 Biomarkers information updated
  • 24 Jul 2014 Discontinued - Phase-I for Metabolic disorders in Switzerland (unspecified route)
  • 24 Jul 2014 Discontinued - Phase-II for Coronary disorders and Hyperlipidaemia in USA, Canada, Czech Republic, Germany, Hungary, New Zealand, Norway, Slovakia and South Africa (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top